Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

Thrombosis and Atherosclerosis Research Institute, Bayer (Germany), University of Pennsylvania, Impact, Bayer (United States), Population Health Research Institute, Clínica Alemana, Universitat Autònoma de Barcelona, Hospital Universitari Germans Trias i Pujol, Lund University, Pirogov Russian National Research Medical University, University Hospital Brno, St. Anne's University Hospital Brno, Hospitais da Universidade de Coimbra, Skåne University Hospital, Instituto Nacional de Neurología y Neurocirugía, Sigmund Freud Privatuniversität Wien, Medical University of Warsaw, University Hospital of Basel, Irmandade da Santa Casa de Misericórdia de São Paulo, Délégation Paris 7, Université Paris Cité, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Helsinki University Hospital, University of Gothenburg, Imperial College London, The University of Western Australia, Sir Charles Gairdner Hospital, Sapienza University of Rome, Semmelweis University, Sanno Medical Center, International University of Health and Welfare, University of Thessaly, Seoul National University Hospital, Vrije Universiteit Brussel, Charité - Universitätsmedizin Berlin, Queen Elizabeth University Hospital, University of Glasgow, Shaare Zedek Medical Center, Selçuk University, Ollscoil na Gaillimhe – University of Galway, Health Research Board, Karl Bremer Hospital, Bayer (France), Janssen (Switzerland), McMaster University, Baylor College of Medicine, University of British Columbia, Sunnybrook Health Science Centre, University of Toronto, Health Sciences Centre, Institute of Cardiology